AU2012326978B2 - Solution for oral administration - Google Patents
Solution for oral administration Download PDFInfo
- Publication number
- AU2012326978B2 AU2012326978B2 AU2012326978A AU2012326978A AU2012326978B2 AU 2012326978 B2 AU2012326978 B2 AU 2012326978B2 AU 2012326978 A AU2012326978 A AU 2012326978A AU 2012326978 A AU2012326978 A AU 2012326978A AU 2012326978 B2 AU2012326978 B2 AU 2012326978B2
- Authority
- AU
- Australia
- Prior art keywords
- acid
- solution
- oral administration
- compound
- glycine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017213570A AU2017213570A1 (en) | 2011-10-19 | 2017-08-11 | Solution for oral administration |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161548859P | 2011-10-19 | 2011-10-19 | |
| US61/548,859 | 2011-10-19 | ||
| PCT/JP2012/077668 WO2013058411A1 (en) | 2011-10-19 | 2012-10-19 | Solution for oral administration |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017213570A Division AU2017213570A1 (en) | 2011-10-19 | 2017-08-11 | Solution for oral administration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2012326978A1 AU2012326978A1 (en) | 2014-05-22 |
| AU2012326978B2 true AU2012326978B2 (en) | 2017-08-31 |
Family
ID=47178263
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012326978A Active AU2012326978B2 (en) | 2011-10-19 | 2012-10-19 | Solution for oral administration |
| AU2017213570A Abandoned AU2017213570A1 (en) | 2011-10-19 | 2017-08-11 | Solution for oral administration |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017213570A Abandoned AU2017213570A1 (en) | 2011-10-19 | 2017-08-11 | Solution for oral administration |
Country Status (35)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| JP6203682B2 (ja) * | 2013-07-10 | 2017-09-27 | 共和薬品工業株式会社 | アリピプラゾール含有水性液剤 |
| RU2633635C1 (ru) * | 2016-06-29 | 2017-10-16 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения |
| WO2017095265A1 (ru) * | 2015-12-01 | 2017-06-08 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения |
| RU2627423C1 (ru) * | 2016-06-29 | 2017-08-08 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения |
| UA124498C2 (uk) * | 2015-12-01 | 2021-09-29 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Фармацевтична композиція для лікування інфекційно-запальних захворювань місцевого застосування і спосіб її одержання та застосування (варіанти) |
| JP6786240B2 (ja) * | 2016-03-31 | 2020-11-18 | 小林製薬株式会社 | 粘性経口組成物 |
| EP3582765B1 (en) * | 2017-10-10 | 2021-04-28 | Vertice Pharma, LLC | Midodrine hydrochloride oral solution and uses thereof |
| JPWO2021029020A1 (cg-RX-API-DMAC10.html) * | 2019-08-13 | 2021-02-18 | ||
| JP2021115288A (ja) * | 2020-01-28 | 2021-08-10 | 青葉化成株式会社 | 液状組成物および液状医療材料 |
| JP2023532085A (ja) | 2020-06-30 | 2023-07-26 | ビレオ システムズ インコーポレイテッド | 膣感染症を治療するための組成物及び方法 |
| US20210401879A1 (en) * | 2020-06-30 | 2021-12-30 | Vireo Systems, Inc. | Compositions for controlling odor and itch and methods of and devices for administering same |
| WO2022218356A1 (zh) * | 2021-04-13 | 2022-10-20 | 上海博志研新药物技术有限公司 | 一种布瑞哌唑口溶膜组合物、其制备方法及应用 |
| CN115414322A (zh) * | 2022-07-05 | 2022-12-02 | 杭州民生药物研究院有限公司 | 一种富马酸卢帕他定口服液体制剂及其制备工艺 |
| CN116966140A (zh) * | 2023-08-18 | 2023-10-31 | 四川阿赛斯生物科技有限公司 | 一种含有布瑞哌唑的口服溶液及其制备方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009039324A1 (en) * | 2007-09-21 | 2009-03-26 | Forest Laboratories Holdings Limited | Soluble dosage forms containing cephem derivatives suitable for parenteral administration |
| US20090286805A1 (en) * | 2005-06-13 | 2009-11-19 | Kazuya Otoda | Solubiliazation preparation |
| US20100179322A1 (en) * | 2005-04-14 | 2010-07-15 | Hiroshi Yamashita | Piperazine-substituted benzothiophenes for treatment of mental disorders |
| WO2012026562A1 (en) * | 2010-08-24 | 2012-03-01 | Otsuka Pharmaceutical Co., Ltd. | Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative |
| WO2012137971A1 (en) * | 2011-04-05 | 2012-10-11 | Otsuka Pharmaceutical Co., Ltd. | Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1420077A (en) * | 1972-04-14 | 1976-01-07 | Unilever Ltd | Process for imparting or enhancing fresh cheese flavour in a food digital transmission systems |
| ES2224634T3 (es) * | 1998-04-29 | 2005-03-01 | Sumitomo Pharmaceuticals Company, Limited | Formulacion oral que comprende biguanida y un acido organico. |
| MY129350A (en) * | 2001-04-25 | 2007-03-30 | Bristol Myers Squibb Co | Aripiprazole oral solution |
| JP4584706B2 (ja) * | 2002-05-03 | 2010-11-24 | イスラエル インスティチュート フォー バイオロジカル リサーチ | 中枢及び末梢神経系障害を治療するための方法及び組成物、並びにそれらに有用な新規の化合物 |
| CA2564180A1 (en) * | 2004-04-22 | 2005-11-03 | Dainippon Sumitomo Pharma Co., Ltd. | Pharmaceutical preparation containing bacterial cell wall skeleton component |
| JP4315393B2 (ja) * | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
| CN101257890B (zh) * | 2005-09-01 | 2012-10-31 | 巴克斯特国际公司 | 含有酸作为增溶剂的阿加曲班制剂 |
| EP2054033A2 (en) * | 2006-07-31 | 2009-05-06 | Asubio Pharma Co., Ltd. | Liquid preparation |
| WO2009038701A2 (en) * | 2007-09-17 | 2009-03-26 | Schering Corporation | Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same |
| US8263652B2 (en) * | 2007-10-31 | 2012-09-11 | Sk Biopharmaceuticals Co., Ltd. | Stabilized pediatric suspension of carisbamate |
| CN102119922A (zh) * | 2011-03-03 | 2011-07-13 | 天津市炜杰科技有限公司 | 以酸作为增溶剂的21(s)阿加曲班静脉注射液 |
-
2012
- 2012-10-18 AR ARP120103877A patent/AR088372A1/es not_active Application Discontinuation
- 2012-10-18 TW TW101138422A patent/TWI632921B/zh active
- 2012-10-18 TW TW106124366A patent/TWI679977B/zh active
- 2012-10-18 JO JOP/2012/0316A patent/JO3190B1/ar active
- 2012-10-19 KR KR1020147013277A patent/KR101856283B1/ko active Active
- 2012-10-19 PT PT127847531T patent/PT2768508T/pt unknown
- 2012-10-19 SG SG11201401273SA patent/SG11201401273SA/en unknown
- 2012-10-19 US US14/352,479 patent/US20140303183A1/en not_active Abandoned
- 2012-10-19 EP EP12784753.1A patent/EP2768508B1/en active Active
- 2012-10-19 WO PCT/JP2012/077668 patent/WO2013058411A1/en not_active Ceased
- 2012-10-19 HR HRP20160989TT patent/HRP20160989T1/hr unknown
- 2012-10-19 PL PL12784753.1T patent/PL2768508T3/pl unknown
- 2012-10-19 EA EA202190445A patent/EA202190445A2/ru unknown
- 2012-10-19 HU HUE12784753A patent/HUE028869T2/en unknown
- 2012-10-19 LT LTEP12784753.1T patent/LT2768508T/lt unknown
- 2012-10-19 MX MX2014004529A patent/MX347309B/es active IP Right Grant
- 2012-10-19 RS RS20160549A patent/RS54967B1/sr unknown
- 2012-10-19 BR BR112014009330A patent/BR112014009330A2/pt not_active Application Discontinuation
- 2012-10-19 ES ES12784753.1T patent/ES2583137T3/es active Active
- 2012-10-19 PH PH1/2014/500816A patent/PH12014500816A1/en unknown
- 2012-10-19 SI SI201230656A patent/SI2768508T1/sl unknown
- 2012-10-19 AU AU2012326978A patent/AU2012326978B2/en active Active
- 2012-10-19 ME MEP-2016-143A patent/ME02459B/me unknown
- 2012-10-19 JP JP2014517060A patent/JP6077534B2/ja active Active
- 2012-10-19 UA UAA201405162A patent/UA111506C2/uk unknown
- 2012-10-19 CN CN201280051524.2A patent/CN103889426A/zh active Pending
- 2012-10-19 MY MYPI2014700955A patent/MY169096A/en unknown
- 2012-10-19 EA EA201490812A patent/EA201490812A1/ru unknown
- 2012-10-19 CA CA2851999A patent/CA2851999C/en active Active
- 2012-10-19 CN CN201711285346.0A patent/CN107823131A/zh active Pending
- 2012-10-19 DK DK12784753.1T patent/DK2768508T3/en active
-
2014
- 2014-04-07 IL IL231988A patent/IL231988A/en active IP Right Grant
- 2014-04-11 ZA ZA2014/02669A patent/ZA201402669B/en unknown
- 2014-04-15 IN IN2987DEN2014 patent/IN2014DN02987A/en unknown
- 2014-04-15 CL CL2014000967A patent/CL2014000967A1/es unknown
- 2014-05-13 CO CO14102721A patent/CO6950486A2/es unknown
-
2016
- 2016-01-21 US US15/003,347 patent/US20160213665A1/en not_active Abandoned
- 2016-07-18 CY CY20161100695T patent/CY1117794T1/el unknown
- 2016-09-29 SM SM201600341T patent/SMT201600341B/it unknown
-
2017
- 2017-02-24 US US15/441,881 patent/US20170182036A1/en not_active Abandoned
- 2017-08-11 AU AU2017213570A patent/AU2017213570A1/en not_active Abandoned
-
2018
- 2018-05-25 US US15/989,294 patent/US20180271858A1/en not_active Abandoned
-
2019
- 2019-09-10 US US16/566,178 patent/US20200171023A1/en not_active Abandoned
-
2020
- 2020-11-13 US US17/097,168 patent/US20210236483A1/en not_active Abandoned
-
2023
- 2023-03-27 US US18/190,839 patent/US20240009186A1/en not_active Abandoned
-
2024
- 2024-08-01 US US18/791,730 patent/US20250099460A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100179322A1 (en) * | 2005-04-14 | 2010-07-15 | Hiroshi Yamashita | Piperazine-substituted benzothiophenes for treatment of mental disorders |
| US20090286805A1 (en) * | 2005-06-13 | 2009-11-19 | Kazuya Otoda | Solubiliazation preparation |
| WO2009039324A1 (en) * | 2007-09-21 | 2009-03-26 | Forest Laboratories Holdings Limited | Soluble dosage forms containing cephem derivatives suitable for parenteral administration |
| WO2012026562A1 (en) * | 2010-08-24 | 2012-03-01 | Otsuka Pharmaceutical Co., Ltd. | Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative |
| WO2012137971A1 (en) * | 2011-04-05 | 2012-10-11 | Otsuka Pharmaceutical Co., Ltd. | Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250099460A1 (en) | Solution for oral administration | |
| CN1512884B (zh) | 阿立哌唑口服溶液 | |
| US11911383B2 (en) | Oral solution formulation | |
| US20250064726A1 (en) | Aqueous suspension suitable for oral administration | |
| US20210213024A1 (en) | Liquid compositions of aprepitant | |
| HK1196773B (en) | Solution for oral administration | |
| NZ623523B2 (en) | Solution for oral administration | |
| LU103368B1 (en) | Pharmaceutical suspension of nilotinib | |
| RU2861060C2 (ru) | Новые пероральные жидкие композиции энзалутамида и способ их изготовления | |
| WO2025172499A1 (en) | Quetiapine liquid formulations | |
| KR20230044359A (ko) | 액제 조성물 | |
| JP5433508B2 (ja) | ゾルピデム酒石酸塩含有内用液剤 | |
| CN120936344A (zh) | 维生素e tpgs作为用于苦味药物的味道掩蔽剂的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |